SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com.
IDO Security (OTCBB: IDOI) $0.0013. Today announced that the Company has been conducting a pilot of the MagShoe™ 3G at a major International Airport in Western Europe. For the past two months MagShoe 3G units have been installed and used on a regular basis in a number of International and European boarding gates.
"This is a major accomplishment in our overall strategy to penetrate the burgeoning European market," stated Mr. Dani Werber, International Sales & Marketing Manager for IDO Security. "So far the reaction of airport officials and the general public has been extremely positive."
Mr. Werber further stated, "The trial is scheduled to run until the end of the year. Although, as requested by the Airport Authority, at this time the exact location cannot be disclosed, once this trial is completed and the MagShoe™ is approved for use, we expect a major order for our shoe scanning device (SSD)."
What They Do: Headquartered in New York with a subsidiary in Israel, IDO Security designs, develops and markets the patented Magshoe™ shoe scanning device (SSD). Magshoe™ fills a critical void in today's metal detectors by extending screening to the lower body and feet. Magshoe™'s "shoes-on" design maximizes security, thoroughness and accuracy while eliminating the need to remove shoes for increased convenience and safety. Ideal for security and loss prevention at virtually any facility, Magshoe™ is currently in use at international airports, cruise lines, government agencies, private homes and more.
SIGA Technologies (Nasdaq: SIGA) $8.56. Today announced that the U.S. Department of Health and Human Services (HHS) has announced HHS's intention to make an award to SIGA of a contract to deliver 1.7 million courses of its smallpox antiviral for the Strategic National Stockpile, pending resolution of issues relating to SIGA's status with the Small Business Administration. The award relates to a Request for Proposal issued by HHS's Biomedical Advanced Research and Development Authority (RFP-BARDA-09-35). The base contract, if finalized, is expected to generate revenues of approximately $500 million, and the entire contract, if all options are exercised, is expected to generate revenues of approximately $2.8 billion.
What They Do: SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense.
Ligand Pharmaceuticals (Nasdaq: LGND) $1.63. Today announced that its partner Pfizer, Inc. (NYSE: PFE) launched Viviant (Bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. Under the brand name Conbriza, the drug is also marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain. Pfizer received manufacturing and marketing approval for the product in Japan in July 2010. Viviant was approved in April 2009 by the European Commission (under the trade name Conbriza) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.
Viviant, a selective estrogen receptor modulator (SERM), is a result of the successful research collaboration between Wyeth (now Pfizer) and Ligand that began in 1994. Pfizer is responsible for the registration and worldwide marketing of bazedoxifene, a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue. Ligand is entitled to receive tiered royalties on net sales of bazedoxifene.
What They Do: Ligand discovers and develops novel drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has been compensated three thousand five hundred dollars by a third party ZR LLC for its services with regards to IDO Security. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com. To follow us on Twitter visit http://twitter.com/SmallCapReview.
